Gastric Cancer: A Review of Risk Factors and New Insights into
Treatment

Saleh      Azadbakht; Parastoo      Baharvand; Mojgan      Saki; Alireza      Moayyedkazemi
Abstract

Gastric cancer (GC) is one of the most frequent cancers in the world, which is ranked the fourth most prevalent cancer and the second leading cause of cancer death. GC is often diagnosed at a progressive phase when the majority of patients are ineligible for remedial therapies in this stage. In addition, the existing systemic chemotherapy exhibits low efficiency and minimum survival benefits. Nowadays, GC therapy is multidisciplinary and multiple option strategies are well-known; therefore, the present study reviewed new insights into chemotherapy agents and various alternative strategies, such as neoadjuvant and adjuvant therapy, nanotherapy, and natural medicines, which are suggested for GC treatment. Moreover, we evaluated current surgical techniques such as endoscopic and laparoscopic resection. We also summarized current findings in pathophysiology, epidemiology, risk factors, diagnosis, prevention, and screening approaches in GC.
Keywords: Stomach carcinoma, epidemiology, diagnosis, treatment, surgery
[1]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin  2011; 61(2): 69-90.
 [http://dx.doi.org/10.3322/caac.20107] [PMID: 21296855]

[2]
 National Cancer Institute. Surveillance, epidemiology, and end results (SEER) program. 2014. Available from: https://seer.cancer.gov/

[3]
Yusefi AR, Bagheri Lankarani K, Bastani P, Radinmanesh M, Kavosi Z. Risk factors for gastric cancer: A systematic review. Asian Pac J Cancer Prev  2018; 19(3): 591-603.
 [PMID: 29579788]

[4]
De B, Rhome R, Jairam V, et al. Gastric adenocarcinoma in young adult patients: Patterns of care and survival in the United States. Gastric Cancer  2018; 21(6): 889-99.

[5]
González CA, Megraud F, Buissonniere A, et al. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: The eurgast-EPIC project. Ann Oncol  2012; 23(5): 1320-4.
 [http://dx.doi.org/10.1093/annonc/mdr384] [PMID: 21917738]

[6]
Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet  1975; 2(7924): 58-60.
 [http://dx.doi.org/10.1016/S0140-6736(75)90498-5] [PMID: 49653]

[7]
Petryszyn P, Chapelle N, Matysiak-Budnik T. Gastric cancer: Where are we heading? Dig Dis  2020; 38(4): 280-5.
 [http://dx.doi.org/10.1159/000506509] [PMID: 32062657]

[8]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2018; 68(6): 394-424.
 [http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]

[9]
Martín-Richard M, Carmona-Bayonas A, Custodio AB, et al. SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). Clin Transl Oncol  2020; 22(2): 236-44.
 [http://dx.doi.org/10.1007/s12094-019-02259-9] [PMID: 31989475]

[10]
Hamashima C. The burden of gastric cancer. Ann Transl Med  2020; 8(12): 734.
 [http://dx.doi.org/10.21037/atm.2020.03.166] [PMID: 32647659]

[11]
Aqel A, Khader Y, Arqoub K, Nimri O. Survival rate of gastric cancer patients in Jordan: Secondary data analysis. JMIR Public Health Surveill  2020; 6(2)e14359
 [http://dx.doi.org/10.2196/14359]

[12]
Zeeneldin AA, Ramadan H, El Gammal MM, Saber MM, Elgamal D, Sherisher MA. Gastric carcinoma at Tanta Cancer Center: A comparative retrospective clinico-pathological study of the elderly versus the non-elderly. J Egypt Natl Canc Inst  2014; 26(3): 127-37.
 [http://dx.doi.org/10.1016/j.jnci.2014.04.002] [PMID: 25150128]

[13]
El Rami FE, Barsoumian HB, Khneizer GW. Hereditary diffuse gastric cancer therapeutic roadmap: Current and novel approaches in a nutshell. Ther Adv Med Oncol  2020; 121758835920967238
 [http://dx.doi.org/10.1177/1758835920967238]

[14]
de Almeida Artifon EL, Marinho FRT. Endoscopic screening for hereditary diffuse gastric cancer: One size does not fit all. Gastrointest Endosc  2018; 87(2): 405-7.
 [http://dx.doi.org/10.1016/j.gie.2017.05.042] [PMID: 29406927]

[15]
Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol  2015; 1(1): 23-32.
 [http://dx.doi.org/10.1001/jamaoncol.2014.168] [PMID: 26182300]

[16]
Thrift AP, Jove AG, Liu Y, Tan MC, El-Serag HB. Associations of duration, intensity, and quantity of smoking with risk of gastric intestinal metaplasia. J Clin Gastroenterol  2020; 56(1): e71-6.
 [http://dx.doi.org/10.1097/MCG.0000000000001479]

[17]
Morais S, Rodrigues S, Amorim L, Peleteiro B, Lunet N. Tobacco smoking and intestinal metaplasia: Systematic review and meta-analysis. Dig Liver Dis  2014; 46(11): 1031-7.
 [http://dx.doi.org/10.1016/j.dld.2014.08.034] [PMID: 25195087]

[18]
Nieminen MT, Salaspuro M. Local acetaldehyde-an essential role in alcohol-related upper gastrointestinal tract carcinogenesis. Cancers (Basel)  2018; 10(1): 11.
 [http://dx.doi.org/10.3390/cancers10010011] [PMID: 29303995]

[19]
LoConte NK, Brewster AM, Kaur JS, Merrill JK, Alberg AJ. Alcohol and cancer: A statement of the american society of clinical oncology. J Clin Oncol  2018; 36(1): 83-93.
 [http://dx.doi.org/10.1200/JCO.2017.76.1155] [PMID: 29112463]

[20]
Eusebi LH, Telese A, Marasco G, Bazzoli F, Zagari RM. Gastric cancer prevention strategies: A global perspective. J Gastroenterol Hepatol  2020; 35(9): 1495-502.
 [http://dx.doi.org/10.1111/jgh.15037] [PMID: 32181516]

[21]
den Hoed CM, Kuipers EJ. Gastric cancer: How can we reduce the incidence of this disease? Curr Gastroenterol Rep  2016; 18(7): 34.
 [http://dx.doi.org/10.1007/s11894-016-0506-0] [PMID: 27184043]

[22]
Kubota T, Shoda K, Konishi H, Okamoto K, Otsuji E. Nutrition update in gastric cancer surgery. Ann Gastroenterol Surg  2020; 4(4): 360-8.
 [http://dx.doi.org/10.1002/ags3.12351]

[23]
Luo Z, Zhou L, Balde AI, et al. Prognostic impact of preoperative prognostic nutritional index in resected advanced gastric cancer: A multicenter propensity score analysis. Eur J Surg Oncol  2019; 45(3): 425-31.
 [http://dx.doi.org/10.1016/j.ejso.2018.09.004] [PMID: 30366877]

[24]
Dewan K, Madan R, Sengupta P, Mandal AK. Diet and gastric cancer. Oncol J India  2020; 4(3): 115-9.
 [http://dx.doi.org/10.4103/oji.oji_47_19]

[25]
Bertuccio P, Rosato V, Andreano A, et al. Dietary patterns and gastric cancer risk: A systematic review and meta-analysis. Ann Oncol  2013; 24: 1450-8.
 [http://dx.doi.org/10.1093/annonc/mdt108]

[26]
Loh YH, Jakszyn P, Luben RN, Mulligan AA, Mitrou PN, Khaw KT. N-Nitroso compounds and cancer incidence: The european prospective investigation into cancer and nutrition (EPIC)-norfolk study. Am J Clin Nutr  2011; 93(5): 1053-61.
 [http://dx.doi.org/10.3945/ajcn.111.012377] [PMID: 21430112]

[27]
Strnad M. Salt and cancer. Acta Med Croatica  2010; 64(2): 159-61.
 [PMID: 20649083]

[28]
You WC, Li JY, Zhang L, et al. Etiology and prevention of gastric cancer: A population study in a high risk area of China. Chin J Dig Dis  2005; 6(4): 149-54.
 [http://dx.doi.org/10.1111/j.1443-9573.2005.00222.x] [PMID: 16246221]

[29]
Xiao JC, Jia CL, Shui PT. Etiology and prevention of gastric cancer karger. Gastrointestinal Tumors  2016; 3(1): 25-36.

[30]
 World Cancer Research Fund International. Diet, Nutrition, physical activity and stomach cancer 2016. Available from: https://www.wcrf.org/wp-content/uploads/2021/02/stomach-cancer-report.pdf

[31]
Steevens J, Schouten LJ, Goldbohm RA, van den Brandt PA. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: A prospective cohort study. Gut  2010; 59(1): 39-48.
 [http://dx.doi.org/10.1136/gut.2009.191080] [PMID: 19828467]

[32]
García Martín R, Matía Cubillo Á. Influence of diet in primary prevention of gastric cancer, in patients infected with Helicobacter pylori. Rev Enferm  2016; 39(5): 33-8.
 [PMID: 27405145]

[33]
Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev  2014; 23(5): 700-13.
 [http://dx.doi.org/10.1158/1055-9965.EPI-13-1057] [PMID: 24618998]

[34]
Pandrani A. Cancer chemoprevention by garlic - A review. Hereditary Genet  2015; 4(2): 1-7.

[35]
Mentis AA, Boziki M, Grigoriadis N, Papavassiliou AG. Helicobacter pylori infection and gastric cancer biology: Tempering a double-edged sword. Cell Mol Life Sci  2019; 76(13): 2477-86.
 [http://dx.doi.org/10.1007/s00018-019-03044-1] [PMID: 30783683]

[36]
Abdoh Q, Kharraz L, Ayoub K, et al. Helicobacter pylori resistance to antibiotics at the An-Najah National University Hospital: A cross-sectional study. Lancet  2018; 391 (Suppl. 2): S32.
 [http://dx.doi.org/10.1016/S0140-6736(18)30398-2] [PMID: 29553431]

[37]
Neale KR, Logan RP. The epidemiology and transmission of Helicobacter pylori infection in children. Aliment Pharmacol Ther  1995; 9 (Suppl. 2): 77-84.
 [PMID: 8547532]

[38]
Beswick EJ, Suarez G, Reyes VE. H pylori and host interactions that influence pathogenesis. World J Gastroenterol  2006; 12(35): 5599-605.

[39]
Talebi Bezmin Abadi A, Taghvaei T, Mohabbati Mobarez A, Vaira G, Vaira D. High correlation of babA 2-positive strains of Helicobacter pylori with the presence of gastric cancer. Intern Emerg Med  2013; 8(6): 497-501.
 [http://dx.doi.org/10.1007/s11739-011-0631-6] [PMID: 21604199]

[40]
Yamaoka Y, Ojo O, Fujimoto S, et al. Helicobacter pylori outer membrane proteins and gastroduodenal disease. Gut  2006; 55(6): 775-81.
 [http://dx.doi.org/10.1136/gut.2005.083014] [PMID: 16322107]

[41]
Kamiya S, Yamaguchi H, Osaki T, Taguchi H. A virulence factor of Helicobacter pylori: Role of heat shock protein in mucosal inflammation after H. pylori infection. J Clin Gastroenterol  1998; 27(1): S35-9.
 [http://dx.doi.org/10.1097/00004836-199800001-00007] [PMID: 9872496]

[42]
Prinz C, Schöniger M, Rad R, et al. Key importance of the Helicobacter pylori adherence factor blood group antigen binding adhesin during chronic gastric inflammation. Cancer Res  2001; 61(5): 1903-9.
 [PMID: 11280745]

[43]
Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science  2003; 301(5636): 1099-102.
 [http://dx.doi.org/10.1126/science.1086871] [PMID: 12934009]

[44]
Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology  2009; 136(6): 1863-73.
 [http://dx.doi.org/10.1053/j.gastro.2009.01.073] [PMID: 19457415]

[45]
Lu H, Wu JY, Beswick EJ, et al. Functional and intracellular signaling differences associated with the Helicobacter pylori AlpAB adhesin from Western and East Asian strains. J Biol Chem  2007; 282(9): 6242-54.
 [http://dx.doi.org/10.1074/jbc.M611178200] [PMID: 17202133]

[46]
Tavakoli A, Monavari SH, Solaymani Mohammadi F, Kiani SJ, Armat S, Farahmand M. Association between Epstein-Barr virus infection and gastric cancer: A systematic review and meta-analysis. BMC Cancer  2020; 20(1): 493.
 [http://dx.doi.org/10.1186/s12885-020-07013-x] [PMID: 32487043]

[47]
Ribeiro J, Oliveira C, Malta M, Sousa H. Epstein-Barr virus gene expression and latency pattern in gastric carcinomas: A systematic review. Future Oncol  2017; 13(6): 567-79.
 [http://dx.doi.org/10.2217/fon-2016-0475] [PMID: 28118740]

[48]
Nogueira C, Mota M, Gradiz R, et al. Prevalence and characteristics of Epstein-Barr virus-associated gastric carcinomas in Portugal. Infect Agent Cancer  2017; 12(1): 41.
 [http://dx.doi.org/10.1186/s13027-017-0151-8] [PMID: 28814970]

[49]
Li X, Zhu X, Wang Y, et al. Prognostic value and association of Lauren classification with VEGF and VEGFR-2 expression in gastric cancer. Oncol Lett  2019; 18(5): 4891-9.
 [http://dx.doi.org/10.3892/ol.2019.10820] [PMID: 31611999]

[50]
Iris ND, Robert OD, David K. WHO classification of tumours editorial board. Histopathology  2021; 76(2): 182-8.
 [http://dx.doi.org/10.1111/his.13975]

[51]
Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. Hoboken, NJ: John Wiley and Sons 2017.
 [http://dx.doi.org/10.1002/9780471420194.tnmc26.pub3]

[52]
Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol  2013; 107(3): 230-6.
 [http://dx.doi.org/10.1002/jso.23262] [PMID: 23129495]

[53]
Milne AN, Carvalho R, Morsink FM, et al. Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol  2006; 19(4): 564-72.
 [http://dx.doi.org/10.1038/modpathol.3800563] [PMID: 16474375]

[54]
Benbrahim Z, Mekkaoui A, Lahmidani N, Ismaili Z, Mellas N. Gastric cancer: An epidemiological overview. Epidemiology (Sunnyvale)  2017; 7(2): 2.
 [http://dx.doi.org/10.4172/2161-1165.1000304]

[55]
Sinning C, Schaefer N, Standop J, Hirner A, Wolff M. Gastric stump carcinoma - epidemiology and current concepts in pathogenesis and treatment. Eur J Surg Oncol  2007; 33(2): 133-9.
 [http://dx.doi.org/10.1016/j.ejso.2006.09.006] [PMID: 17071041]

[56]
Luo W, Fedda F, Lynch P, Tan D. CDH1 Gene and hereditary diffuse gastric cancer syndrome: Molecular and histological alterations and implications for diagnosis and treatment. Front Pharmacol  2018; 9: 1421.
 [http://dx.doi.org/10.3389/fphar.2018.01421] [PMID: 30568591]

[57]
Kaurah P, Huntsman DG.  Hereditary diffuse gastric cancer. GeneReviews 1993-2019. Available from: https://medlineplus.gov/genetics/-condition/hereditary-diffuse-gastric-cancer/#:~:text=Hereditary-%20diffuse%20gastric%20cancer%20-(HDGC,there%20is%20no%- 20solid%20tumor

[58]
Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol  2012; 6(2): 140-6.
 [http://dx.doi.org/10.1016/j.molonc.2012.01.010] [PMID: 22356776]

[59]
Ye DM, Xu G, Ma W, et al. Significant function and research progress of biomarkers in gastric cancer. Oncol Lett  2020; 19(1): 17-29.
 [PMID: 31897111]

[60]
Zhou C, Zhong X, Song Y, Shi J, Zhonghua W, Zhexu G. Prognostic biomarkers for gastric cancer: An umbrella review of the evidence. Front Oncol  2019; 2019: 01321.
 [http://dx.doi.org/10.3389/fonc.2019.01321]

[61]
Grávalos C, Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol  2008; 19(9): 1523-9.
 [http://dx.doi.org/10.1093/annonc/mdn169] [PMID: 18441328]

[62]
Komuro A, Yashiro M, Iwata C, et al. Diffuse-type gastric carcinoma: Progression, angiogenesis, and transforming growth factor beta signaling. J Natl Cancer Inst  2009; 101(8): 592-604.
 [http://dx.doi.org/10.1093/jnci/djp058] [PMID: 19351925]

[63]
Xing X, Guo J, Ding G, et al. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. OncoImmunology  2017; 7(3)e1356144
 [http://dx.doi.org/10.1080/2162402X.2017.1356144] [PMID: 29399387]

[64]
Guo CY, Xu XF, Wu JY, Liu SF. PCR-SSCP-DNA sequencing method in detecting PTEN gene mutation and its significance in human gastric cancer. World J Gastroenterol  2008; 14(24): 3804-11.
 [http://dx.doi.org/10.3748/wjg.14.3804] [PMID: 18609703]

[65]
Hayashi K, Metzger R, Salonga D, et al. High frequency of simultaneous loss of p16 and p16beta gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach. Oncogene  1997; 15(12): 1481-8.
 [http://dx.doi.org/10.1038/sj.onc.1201295] [PMID: 9333024]

[66]
Qiao W, Wang T, Zhang L, Tang Q, Wang D, Sun H. Association between single genetic polymorphisms of MDR1 gene and gastric cancer susceptibility in Chinese. Med Oncol  2013; 30(3): 643.
 [http://dx.doi.org/10.1007/s12032-013-0643-3] [PMID: 23801278]

[67]
Wong H, Yau T. Targeted therapy in the management of advanced gastric cancer: Are we making progress in the era of personalized medicine? Oncologist  2012; 17(3): 346-58.
 [http://dx.doi.org/10.1634/theoncologist.2011-0311] [PMID: 22334453]

[68]
Kitoh T, Yanai H, Saitoh Y, et al. Increased expression of matrix metalloproteinase-7 in invasive early gastric cancer. J Gastroenterol  2004; 39(5): 434-40.
 [http://dx.doi.org/10.1007/s00535-003-1316-3] [PMID: 15175941]

[69]
Yu P, Du Y, Cheng X, Yu Q, Huang L, Dong R. Expression of multidrug resistance-associated proteins and their relation to postoperative individualized chemotherapy in gastric cancer. World J Surg Oncol  2014; 12(1): 307.
 [http://dx.doi.org/10.1186/1477-7819-12-307] [PMID: 25304659]

[70]
Sandusky GE, Mintze KSE, Pratt SE, Dantzig AH. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology  2002; 41(1): 65-74.
 [http://dx.doi.org/10.1046/j.1365-2559.2002.01403.x] [PMID: 12121239]

[71]
Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res  1996; 2(10): 1679-84.
 [PMID: 9816116]

[72]
Arici DS, Tuncer E, Ozer H, Simek G, Koyuncu A. Expression of retinoblastoma and cyclin D1 in gastric carcinoma. Neoplasma  2009; 56(1): 63-7.
 [http://dx.doi.org/10.4149/neo_2009_01_63] [PMID: 19152247]

[73]
Feakins RM, Mulcahy HE, Quaglia A, Jawhari A, Zhang Z, Patchett SE. p27(Kip1) loss does not predict survival in patients with advanced gastric carcinoma. Cancer  2000; 89(8): 1684-91.
 [http://dx.doi.org/10.1002/1097-0142(20001015)89:8<1684:AID-CNCR6>3.0.CO;2-6] [PMID: 11042561]

[74]
Wu J, Liu X, Cai H, Wang Y. Prediction of tumor recurrence after curative resection in gastric carcinoma based on bcl-2 expression. World J Surg Oncol  2014; 12(1): 40.
 [http://dx.doi.org/10.1186/1477-7819-12-40] [PMID: 24555747]

[75]
Fukaya M, Isohata N, Ohta H, et al. Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. Gastroenterology  2006; 131(1): 14-29.
 [http://dx.doi.org/10.1053/j.gastro.2006.05.008] [PMID: 16831586]

[76]
Bass AJ, Thorsson V, Shmulevich I, et al. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature  2014; 513(7517): 202-9.
 [http://dx.doi.org/10.1038/nature13480] [PMID: 25079317]

[77]
Boltin D, Niv Y. Mucins in gastric cancer-an update. J Gastrointest Dig Syst  2013; 3(123): 15519.
 [PMID: 24077811]

[78]
Mammano E, Belluco C, Sciro M, et al. Epidermal growth factor receptor (EGFR): Mutational and protein expression analysis in gastric cancer. Anticancer Res  2006; 26(5A): 3547-50.
 [PMID: 17094480]

[79]
Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med  2015; 21(5): 449-56.
 [http://dx.doi.org/10.1038/nm.3850] [PMID: 25894828]

[80]
Yu G, Wang J, Chen Y, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res  2009; 15(5): 1821-9.
 [http://dx.doi.org/10.1158/1078-0432.CCR-08-2138] [PMID: 19223493]

[81]
Riquelme I, Saavedra K, Espinoza JA, et al. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget  2015; 6(28): 24750-79.
 [http://dx.doi.org/10.18632/oncotarget.4990] [PMID: 26267324]

[82]
Hamashima C, Ogoshi K, Narisawa R, et al. Impact of endoscopic screening on mortality reduction from gastric cancer. World J Gastroenterol  2015; 21(8): 2460-6.
 [http://dx.doi.org/10.3748/wjg.v21.i8.2460] [PMID: 25741155]

[83]
Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: Systematic review and meta-analysis of randomised controlled trials. BMJ  2014; 348: g3174.
 [http://dx.doi.org/10.1136/bmj.g3174] [PMID: 24846275]

[84]
Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut  2005; 54(6): 735-8.
 [http://dx.doi.org/10.1136/gut.2004.056549] [PMID: 15888771]

[85]
Ge S, Feng X, Shen L, Wei Z, Zhu Q, Sun J. Association between habitual dietary salt intake and risk of gastric cancer: A systematic review of observational studies. Gastroenterol Res Pract  2012; 2012808120
 [http://dx.doi.org/10.1155/2012/808120] [PMID: 23125851]

[86]
Zhang Z, Xu G, Ma M, Yang J, Liu X. Dietary fiber intake reduces risk for gastric cancer: A meta-analysis. Gastroenterology  2013; 145(1): 113-120.e3.
 [http://dx.doi.org/10.1053/j.gastro.2013.04.001] [PMID: 23567349]

[87]
Sasazuki S, Inoue M, Hanaoka T, Yamamoto S, Sobue T, Tsugane S. Green tea consumption and subsequent risk of gastric cancer by subsite: The JPHC Study. Cancer Causes Control  2004; 15(5): 483-91.
 [http://dx.doi.org/10.1023/B:CACO.0000036449.68454.42] [PMID: 15286468]

[88]
Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol  2010; 28(18): 2952-7.
 [http://dx.doi.org/10.1200/JCO.2009.26.0695] [PMID: 20479409]

[89]
Karczewski J, Begier-Krasińska B, Staszewski R, Popławska E, Gulczynska-Elhadi K, Dobrowolska A. Obesity and the risk of gastrointestinal cancers. Dig Dis Sci  2019; 64(10): 2740-9.
 [http://dx.doi.org/10.1007/s10620-019-05603-9] [PMID: 30968228]

[90]
Wilson JMG, Jungner G.  Principles and practice of screening for disease. Geneva, Switzerland: WHO 1968; p. 163. Available from: http://whqlibdoc.who.int/php/WHO_PHP_34.pdf

[91]
Hamashima C, Shibuya D, Yamazaki H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol  2008; 38(4): 259-67.
 [http://dx.doi.org/10.1093/jjco/hyn017] [PMID: 18344316]

[92]
Choi KS, Jun JK, Lee HY, et al. Performance of gastric cancer screening by endoscopy testing through the National Cancer Screening Program of Korea. Cancer Sci  2011; 102(8): 1559-64.
 [http://dx.doi.org/10.1111/j.1349-7006.2011.01982.x] [PMID: 21564421]

[93]
Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: Progression in early diagnosis and prognosis. (Review). Oncol Lett  2015; 9(4): 1502-8.
 [http://dx.doi.org/10.3892/ol.2015.2959] [PMID: 25788990]

[94]
Feng F, Tian Y, Xu G, et al. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC Cancer  2017; 17(1): 737.
 [http://dx.doi.org/10.1186/s12885-017-3738-y] [PMID: 29121872]

[95]
Kumagai K, Hiki N, Nunobe S, et al. Totally laparoscopic pylorus-preserving gastrectomy for early gastric cancer in the middle stomach: Technical report and surgical outcomes. Gastric Cancer  2015; 18(1): 183-7.
 [http://dx.doi.org/10.1007/s10120-014-0337-3] [PMID: 24481853]

[96]
Chen ZD, Zhang PF, Xi HQ, Wei B, Chen L, Tang Y. Recent advances in the diagnosis, staging, treatment, and prognosis of advanced gastric cancer: A literature review Front Med  2021; 2021: 1962.

[97]
Park JY, Yu B, Park KB, Kwon OK, Lee SS, Chung HY. Impact of palliative gastrectomy in patients with incurable gastric cancer. Medicina (Kaunas)  2021; 57(3): 198.
 [http://dx.doi.org/10.3390/medicina57030198] [PMID: 33652574]

[98]
Beom SH, Choi YY, Baek SE, et al. Multidisciplinary treatment for patients with stage IV gastric cancer: The role of conversion surgery following chemotherapy. BMC Cancer  2018; 18(1): 1116.
 [http://dx.doi.org/10.1186/s12885-018-4998-x] [PMID: 30442107]

[99]
Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer  2017; 20(S1): 128-34.
 [http://dx.doi.org/10.1007/s10120-016-0684-3] [PMID: 28028665]

[100]
Irino T, Matsuda S, Wada N, Kawakubo H, Kitagawa Y. Essential updates 2019/2020: Perioperative and surgical management of gastric cancer. AGSurg  2019/2020; 5(2): 162-72.
 [http://dx.doi.org/10.1002/ags3.12438]

[101]
Li JQ, He D, Liang YX. Current status of extended ‘D2 plus’ lymphadenectomy in advanced gastric cancer. Oncol Lett  2021; 21(6): 467.
 [http://dx.doi.org/10.3892/ol.2021.12728] [PMID: 33907577]

[102]
Li S, Gu L, Shen Z, Mao D, Khadaroo PA, Su H. A meta-analysis of comparison of proximal gastrectomy with double-tract reconstruction and total gastrectomy for proximal early gastric cancer. BMC Surg  2019; 19(1): 117.
 [http://dx.doi.org/10.1186/s12893-019-0584-7] [PMID: 31438918]

[103]
Joshi Smita S, Badgwell Brian D. Current treatment and recent progress in gastric cancer. CA Cancer J Clin  2021; 2021: 1-16.

[104]
Xue J, Yang H, Huang S, Zhou T, Zhang X, Zu G. Comparison of the overall survival of proximal and distal gastric cancer after gastrectomy: A systematic review and meta-analysis. World J Surg Oncol  2021; 19(1): 17.
 [http://dx.doi.org/10.1186/s12957-021-02126-4] [PMID: 33468158]

[105]
Desiderio J, Sagnotta A, Terrenato I, et al. Gastrectomy for stage IV gastric cancer: A comparison of different treatment strategies from the SEER database. Sci Rep  2021; 11(1): 7150.
 [http://dx.doi.org/10.1038/s41598-021-86352-6] [PMID: 33785761]

[106]
Degiuli M, Sasako M, Ponti A. Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg  2010; 97(5): 643-9.
 [http://dx.doi.org/10.1002/bjs.6936] [PMID: 20186890]

[107]
Cho JH, Cha SW, Kim HG, et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: A comparison study to surgery using propensity score-matched analysis. Surg Endosc  2016; 30(9): 3762-73.
 [http://dx.doi.org/10.1007/s00464-015-4672-1] [PMID: 26659226]

[108]
Fukunaga S, Nagami Y, Shiba M, et al. Long-term prognosis of expanded-indication differentiated-type early gastric cancer treated with endoscopic submucosal dissection or surgery using propensity score analysis. Gastrointest Endosc  2017; 85(1): 143-52.
 [http://dx.doi.org/10.1016/j.gie.2016.06.049] [PMID: 27365265]

[109]
Lee A, Chung H. Endoscopic resection of undifferentiated-type early gastric cancer. J Gastric Cancer  2020; 20(4): 345-54.
 [http://dx.doi.org/10.5230/jgc.2020.20.e37] [PMID: 33425437]

[110]
Lee S, Choi KD, Han M, et al. Long-term outcomes of endoscopic submucosal dissection versus surgery in early gastric cancer meeting expanded indication including undifferentiated-type tumors: A criteria-based analysis. Gastric Cancer  2018; 21(3): 490-9.
 [http://dx.doi.org/10.1007/s10120-017-0772-z] [PMID: 29052052]

[111]
Tsekrekos A, Triantafyllou T, Klevebro F, et al. Implementation of minimally invasive gastrectomy for gastric cancer in a western tertiary referral center. BMC Surg  2020; 20(1): 157.
 [http://dx.doi.org/10.1186/s12893-020-00812-w] [PMID: 32677942]

[112]
Straatman J, van der Wielen N, Cuesta MA, et al. Surgical techniques, open versus minimally invasive gastrectomy after chemotherapy (STOMACH trial): Study protocol for a randomized controlled trial. Trials  2015; 16(1): 123.
 [http://dx.doi.org/10.1186/s13063-015-0638-9] [PMID: 25873249]

[113]
Li Z, Shan F, Ying X, et al. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: A randomized clinical trial. JAMA Surg  2019; 154(12): 1093-101.
 [http://dx.doi.org/10.1001/jamasurg.2019.3473] [PMID: 31553463]

[114]
Beeharry MK, Zhang TQ, Liu WT, Gang ZZ. Optimization of perioperative approaches for advanced and late stages of gastric cancer: Clinical proposal based on literature evidence, personal experience, and ongoing trials and research. World J Surg Oncol  2020; 18(1): 51.
 [http://dx.doi.org/10.1186/s12957-020-01819-6] [PMID: 32151257]

[115]
Cunningham D, Allum WH, Stenning SP, et al. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med  2006; 355(1): 11-20.
 [http://dx.doi.org/10.1056/NEJMoa055531] [PMID: 16822992]

[116]
Reddavid R, Sofia S, Chiaro P, et al. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? World J Gastroenterol  2018; 24(2): 274-89.
 [http://dx.doi.org/10.3748/wjg.v24.i2.274] [PMID: 29375213]

[117]
Wang XZ, Zeng ZY, Ye X, Sun J, Zhang ZM, Kang WM. Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World J Gastrointest Oncol  2020; 12(1): 37-53.
 [http://dx.doi.org/10.4251/wjgo.v12.i1.37] [PMID: 31966912]

[118]
Mosa ASM, Hossain AM, Lavoie BJ, Yoo I. Patient-related risk factors for chemotherapy-induced nausea and vomiting: A systematic review. Front Pharmacol  2020; 11: 329.
 [http://dx.doi.org/10.3389/fphar.2020.00329]

[119]
Wang J, Shi H, Yang G. Combined intra-arterial and intravenous chemotherapy for unresectable, advanced gastric cancer has an improved curative effect compared with intravenous chemotherapy only. Oncol Lett  2018; 15: 5662-70.

[120]
Arai H, Nakajima TE. Recent developments of systemic chemotherapy for gastric cancer. Cancers (Basel)  2020; 12(5): 1100.
 [http://dx.doi.org/10.3390/cancers12051100] [PMID: 32354119]

[121]
Xu Wentao, Beeharry Maneesh K, Liu W. Preoperative chemotherapy for gastric cancer: Personal interventions and precision medicine. BioMed Res Int  2016; 20163923585
 [http://dx.doi.org/10.1155/2016/3923585]

[122]
Choi IS, Choi M, Lee JH, et al. Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study. PLoS One  2018; 13(6)e0198544
 [http://dx.doi.org/10.1371/journal.pone.0198544] [PMID: 29879177]

[123]
Jena J, Ranjan R, Ranjan P, Sarangi MK. A study on natural anticancer plants. Int J Pharm Chemsci  2012; 1(1): 365-8.

[124]
Asadi-Samani M, Kooti W, Aslani E, Shirzad H. A systematic review of iran’s medicinal plants with anticancer effects. J Evid Based Complementary Altern Med  2015; 2015: 1-11.
 [PMID: 26297173]

[125]
Sheng J, Zou X, Cheng Z, et al. Recent advances in herbal medicines for digestive system malignancies. Front Pharmacol  2018; 9: 1249.
 [http://dx.doi.org/10.3389/fphar.2018.01249] [PMID: 30524272]

[126]
Lee Yu Kyung. Bae K, Yoo H, Seung-Hun Cho. Benefit of adjuvant traditional herbal medicine with chemotherapy for resectable gastric C. Integr Cancer Ther  2018; 17(3): 619-27.
 [http://dx.doi.org/10.1177/1534735417753542] [PMID: 29614889]

[127]
Kintzios SE, Baberaki MG. Plants that fight cancer. US: CRC press LLC 2004.

[128]
Xie HX, Xu ZY, Tang JN, et al. Effect of Huaier on the proliferation and apoptosis of human gastric cancer cells through modulation of the PI3K/AKT signaling pathway. Exp Ther Med  2015; 10(3): 1212-8.
 [http://dx.doi.org/10.3892/etm.2015.2600] [PMID: 26622467]

[129]
Xu Z, Zheng G, Wang Y, et al. Aqueous huaier extract suppresses gastric cancer metastasis and epithelial to mesenchymal transition by targeting twist. J Cancer  2017; 8(18): 3876-86.
 [http://dx.doi.org/10.7150/jca.20380] [PMID: 29151976]

[130]
Yi T, Zhuang L, Song G, Zhang B, Li G, Hu T. Akt signaling is associated with the berberine-induced apoptosis of human gastric cancer cells. Nutr Cancer  2015; 67(3): 523-31.
 [http://dx.doi.org/10.1080/01635581.2015.1004733] [PMID: 25837881]

[131]
Luo C, Zhong HJ, Zhu LM, et al. Inhibition of matrine against gastric cancer cell line MNK45 growth and its anti-tumor mechanism. Mol Biol Rep  2012; 39(5): 5459-64.
 [http://dx.doi.org/10.1007/s11033-011-1346-5] [PMID: 22207169]

[132]
Li HL, Wu H, Zhang BB, Shi HL, Wu XJ. MAPK pathways are involved in the inhibitory effect of berberine hydrochloride on gastric cancer MGC 803 cell proliferation and IL-8 secretion in vitro and in vivo. Mol Med Rep  2016; 14(2): 1430-8.
 [http://dx.doi.org/10.3892/mmr.2016.5361] [PMID: 27278862]

[133]
Zheng LC, Yang MD, Kuo CL, et al. Norcantharidin-induced apoptosis of AGS human gastric cancer cells through reactive oxygen species production, and caspase- and mitochondria-dependent signaling pathways. Anticancer Res  2016; 36(11): 6031-42.
 [http://dx.doi.org/10.21873/anticanres.11192] [PMID: 27793930]

[134]
Zheng J, Li C, Wu X, et al. Huaier polysaccharides suppresses hepatocarcinoma MHCC97-H cell metastasis via inactivation of EMT and AEG-1 pathway. Int J Biol Macromol  2014; 64: 106-10.
 [http://dx.doi.org/10.1016/j.ijbiomac.2013.11.034] [PMID: 24321491]

[135]
Auyeung KK, Woo PK, Law PC, Ko JK. Astragalus saponins modulate cell invasiveness and angiogenesis in human gastric adenocarcinoma cells. J Ethnopharmacol  2012; 141(2): 635-41.
 [http://dx.doi.org/10.1016/j.jep.2011.08.010] [PMID: 21864667]

[136]
Zhang JW, Su K, Shi WT, et al. Matrine inhibits the adhesion and migration of BCG823 gastric cancer cells by affecting the structure and function of the vasodilator-stimulated phosphoprotein (VASP). Acta Pharmacol Sin  2013; 34(8): 1084-92.
 [http://dx.doi.org/10.1038/aps.2013.15] [PMID: 23685951]

[137]
Guo B, Zhang T, Su J, Wang K, Li X. Oxymatrine targets EGFR(p-Tyr845) and inhibits EGFR-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells. Cancer Chemother Pharmacol  2015; 75(2): 353-63.
 [http://dx.doi.org/10.1007/s00280-014-2651-1] [PMID: 25527205]

[138]
Zhao X, Xu L, Zheng L, et al. Potent effects of dioscin against gastric cancer in vitro and in vivo. Phytomedicine  2016; 23(3): 274-82.
 [http://dx.doi.org/10.1016/j.phymed.2016.01.012] [PMID: 26969381]

[139]
Lee S-H, Choi W-C, Kim K-S, Park J-W, Lee SH, Yoon SW. Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract. J Altern Complement Med  2010; 16(4): 497-500.
 [http://dx.doi.org/10.1089/acm.2008.0237] [PMID: 20423218]

[140]
Chen J, Wang J, Lin L, et al. Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. Mol Cancer Ther  2012; 11(2): 277-87.
 [http://dx.doi.org/10.1158/1535-7163.MCT-11-0648] [PMID: 22203730]

[141]
Ye Y, Fang Y, Xu W, Wang Q, Zhou J, Lu R. 3,3′-Diindolylmethane induces anti-human gastric cancer cells by the miR-30e-ATG5 modulating autophagy. Biochem Pharmacol  2016; 115: 77-84.
 [http://dx.doi.org/10.1016/j.bcp.2016.06.018] [PMID: 27372603]

[142]
Zhou X, Liu M, Ren Q, et al. Oral and injectable Marsdenia tenacissima extract (MTE) as adjuvant therapy to chemotherapy for gastric cancer: A systematic review. BMC Complement Altern Med  2019; 19(1): 366.
 [http://dx.doi.org/10.1186/s12906-019-2779-y] [PMID: 31830977]

[143]
Yao J-N, Zhang X-X, Zhang Y-Z, et al. Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells. Invest New Drugs  2019; 37(6): 1300-8.
 [http://dx.doi.org/10.1007/s10637-019-00767-7] [PMID: 30929157]

[144]
Zhu X, Jiang X, Li A, et al. S-allylmercaptocysteine suppresses the growth of human gastric cancer xenografts through induction of apoptosis and regulation of MAPK and PI3K/Akt signaling pathways. Biochem Biophys Res Commun  2017; 491(3): 821-6.
 [http://dx.doi.org/10.1016/j.bbrc.2017.06.107] [PMID: 28642133]

[145]
Cheng AL, Hsu C-H, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res  2001; 21(4B): 2895-900.
 [PMID: 11712783]

[146]
Mu J, Liu T, Jiang L, et al. The traditional chinese medicine baicalein potently inhibits gastric cancer cells. J Cancer  2016; 7(4): 453-61.
 [http://dx.doi.org/10.7150/jca.13548] [PMID: 26918059]

[147]
Lissoni P, Rovelli F, Brivio F, et al. A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer. In Vivo  2009; 23(1): 171-5.
 [PMID: 19368145]

[148]
Wen C, Wang H, Wu X, et al. ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin. Cell Death Dis  2019; 10(11): 809-16.
 [http://dx.doi.org/10.1038/s41419-019-2035-x] [PMID: 31649256]

[149]
Zhang Y, Liu S, Feng Q, et al. Perilaldehyde activates AMP-activated protein kinase to suppress the growth of gastric cancer via induction of autophagy. J Cell Biochem  2018; 120(2): 1716-25.
 [http://dx.doi.org/10.1002/jcb.27491] [PMID: 30378150]

[150]
Xu J, Chen Y, Yang R, et al. Cucurbitacin B inhibits gastric cancer progression by suppressing STAT3 activity. Arch Biochem Biophys  2020; 684108314
 [http://dx.doi.org/10.1016/j.abb.2020.108314] [PMID: 32088220]

[151]
Li W-Q, Zhang J-Y, Ma J-L, et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: Follow-up of a randomized intervention trial. BMJ  2019; 366: l5016.
 [http://dx.doi.org/10.1136/bmj.l5016] [PMID: 31511230]

[152]
Ishiguro K, Ando T, Maeda O, et al. Ginger ingredients reduce viability of gastric cancer cells via distinct mechanisms. Biochem Biophys Res Commun  2007; 362(1): 218-23.
 [http://dx.doi.org/10.1016/j.bbrc.2007.08.012] [PMID: 17706603]

[153]
Peng J, Liang X. Progress in research on gold nanoparticles in cancer management. Medicine (Baltimore)  2019; 98(18)e15311
 [http://dx.doi.org/10.1097/MD.0000000000015311] [PMID: 31045767]

[154]
Beik J, Khademi S, Attaran N, et al. A Nanotechnology-based strategy to increase the efficiency of cancer diagnosis and therapy: Folate-conjugated gold nanoparticles. Curr Med Chem  2017; 24(39): 4399-416.
 [http://dx.doi.org/10.2174/0929867324666170810154917] [PMID: 28799495]

[155]
Aghebati-Maleki A, Dolati S, Ahmadi M, et al. Nanoparticles and cancer therapy: Perspectives for application of nanoparticles in the treatment of cancers. J Cell Physiol  2020; 235(3): 1962-72.
 [http://dx.doi.org/10.1002/jcp.29126] [PMID: 31441032]

[156]
Salapa J, Bushman A, Lowe K, Irudayaraj J. Nano drug delivery systems in upper gastrointestinal cancer therapy. Nano Converg  2020; 7(1): 38.
 [http://dx.doi.org/10.1186/s40580-020-00247-2]

[157]
Li Z, Ao S, Bu Z, et al. Clinical study of harvesting lymph nodes with carbon nanoparticles in advanced gastric cancer: A prospective randomized trial. World J Surg Oncol  2016; 14(1): 88.
 [http://dx.doi.org/10.1186/s12957-016-0835-3] [PMID: 27009101]

[158]
Xu X, Wang L, Xu HQ, Huang XE, Qian YD, Xiang J. Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev  2013; 14(4): 2591-4.
 [http://dx.doi.org/10.7314/APJCP.2013.14.4.2591] [PMID: 23725180]

[159]
Yang J, Teng Y, Fu Y, Zhang C. Chlorins e6 loaded silica nanoparticles coated with gastric cancer cell membrane for tumor specific photodynamic therapy of gastric cancer. Int J Nanomedicine  2019; 14: 5061-71.
 [http://dx.doi.org/10.2147/IJN.S202910] [PMID: 31371947]

[160]
Kubota T, Kuroda S, Kanaya N, et al. HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer. Nanomedicine  2018; 14(6): 1919-29.
 [http://dx.doi.org/10.1016/j.nano.2018.05.019] [PMID: 29885899]

[161]
Ghanbari M, Asadi A, Rostamzadeh S. Study of the cytotoxicity effect of doxorubicin-loaded/folic acid-targeted super paramagnetic iron oxide nanoparticles on AGS cancer cell line. J Nanomed Nanotechnol  2016; 7(2): 368.
 [http://dx.doi.org/10.4172/2157-7439.1000368]

[162]
Forte M, Iachetta G, Tussellino M, et al. Polystyrene nanoparticles internalization in human gastric adenocarcinoma cells. TIV  2016; 31: 126-36.
 [http://dx.doi.org/10.1016/j.tiv.2015.11.006] [PMID: 26585375]

[163]
Mousavi B, Tafvizi F, Zaker Bostanabad S. Green synthesis of silver nanoparticles using Artemisia turcomanica leaf extract and the study of anti-cancer effect and apoptosis induction on gastric cancer cell line (AGS). Artif Cells Nanomedicine Biotechnol  2018; 46 (Suppl. 1): 499-510.

[164]
Liu D, Li X, Chen C, et al. Target-specific delivery of oxaliplatin to HER2-positive gastric cancer cells in vivo using oxaliplatin-au-fe3o4-herceptin nanoparticles. Oncol Lett  2018; 15(5): 8079-87.
 [http://dx.doi.org/10.3892/ol.2018.8323] [PMID: 29731915]

[165]
Cui D, Zhang C, Liu B, Shu Y, Du T. Regression of gastric cancer by systemic injection of RNA nanoparticles carrying both ligand and siRNA 2015.
 [http://dx.doi.org/10.1038/srep10726]

[166]
Mohammadian F, Abhari A, Dariushnejad H, et al. Upregulation of Mir-34a in AGS gastric cancer cells by a PLGA-PEG-PLGA chrysin nano formulation. Asian Pac J Cancer Prev  2015; 16(18): 8259-63.
 [http://dx.doi.org/10.7314/APJCP.2015.16.18.8259] [PMID: 26745070]
Cite As
Current Cancer Therapy Reviews

Gastric Cancer: A Review of Risk Factors and New Insights into Treatment

Abstract
